Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Rofecoxib Significantly Reduces The Risk Of Recurrence Of Colorectal Polyps

01.09.2006
Data from the APPROVe Trial Shows Rofecoxib Effective in Broad, At-Risk Population

The use of the cyclooxygenase-2 (COX-2) inhibitor rofecoxib (Vioxx®) reduces the risk of colorectal adenomas, according to data being published in Gastroenterology, the journal for the members of the American Gastroenterological Association (AGA). The study, “A Randomized Trial of Rofecoxib for the Chemoprevention of Colorectal Adenomas,” is scheduled for publication in December, but was released on-line in August due to the significance of the findings. The manuscript can be found on-line.

John Baron, MD, lead author of the paper and a professor at Dartmouth Medical School, has been studying chemoprevention of colorectal cancer for more than twenty years. “These are exciting findings,” he said. “They show once again the potential for non-steroidal anti-inflammatory drugs, or NSAIDs, to interfere with the development of cancer in the colon and rectum.”

Extensive data have suggested previously that aspirin and non-selective nonsteroidal anti-inflammatory drugs (NSAIDs) could reduce colon cancer risk. This study now demonstrates such an effect for a selective COX-2 inhibitor in a placebo-controlled randomized study. While previous randomized studies have shown that COX-2 inhibitors can lower the risk of adenoma in patients with a rare genetic syndrome called familial adenomatous polyposis (FAP), the effect in the broad population of people at risk for colorectal cancer has not been previously demonstrated. More commonly referred to as “polyps,” adenomas are benign tumors that are precursors to colon cancer, and are commonly found in older adults in the United States and worldwide.

The APPROVe (Adenomatous Polyp Prevention on Vioxx) study was a randomized, placebo-controlled, double-blind trial funded by Merck Research Laboratories. Study results showed that patients taking rofecoxib had a lower recurrence rate of adenomas than those taking placebo (41 percent vs 55 percent; p

About the Study

The study included 2,587 evaluable patients with a recent history of confirmed colorectal polyps followed at 108 sites in the United States and abroad. After removal of all polyps, patients were randomized to receive either placebo or 25 mg rofecoxib (the average daily recommended dose) on a daily basis. The primary endpoint was all polyps diagnosed during the three-year treatment period based upon colonoscopies conducted one year and three years after baseline. In addition, an extension to the APPROVe study was conducted to assess recurrence of adenomas in the year following the end of the three years’ treatment through colonoscopy at year four.

Patients treated with rofecoxib experienced more serious adverse events, including significant upper gastrointestinal events and, as reported previously, increased risks of thrombotic cardiovascular events (Bresalier et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. NEJM 2005;352:1092-102). Dr. Baron does not believe that the side effects will derail the eventual development of effective chemoprevention.

“While the toxicity of the currently available COX-2 inhibitors may be problematic, the demonstration of efficacy certainly implies that other agents may be suitable for longer term use,” he said.

Although it is not known how rofecoxib interferes with carcinogenesis, inhibition of COX-2 has been thought to play a role. Other mechanisms are possible, however, and scientists are actively seeking to understand exactly how non-steroidal anti-inflammatory drugs alter pathways that lead to cancer.

“Colorectal cancer is the second leading cause of cancer death in the United States1, so it is important to aggressively research and develop potential chemopreventive agents to help patients who are at the highest risk of developing the disease,” according to Anil K. Rustgi, MD, editor of Gastroenterology and Chief of Gastroenterology at the University of Pennsylvania School of Medicine. “It is important to not hold onto this information until December so the results of this study can be added to the body of knowledge about cancer prevention that could potentially help physicians care for their patients.”

About Colorectal Cancer

Colorectal cancer is the third most common cancer in men and women2 and the second leading cause of cancer death1. However it is one of the most easily prevented cancers, and has a relatively good prognosis when diagnosed and treated early. An individual’s risk of colon cancer increases with age, therefore, all men and women should undergo a baseline colonoscopy at age 50, then again at the recommendation of their gastroenterologist. Eighty to 90 million Americans (approximately 25 percent of the US population) are considered at risk because of age or other factors, and more women over the age of 75 die from colorectal cancer than from breast cancer3.

About the AGA Institute

The American Gastroenterological Association (AGA) is dedicated to the mission of advancing the science and practice of gastroenterology. Founded in 1897, the AGA is one of the oldest medical-specialty societies in the United States. Comprised of two non-profit organizations—the AGA and the AGA Institute—our more than 15,000 members include physicians and scientists who research, diagnose and treat disorders of the gastrointestinal tract and liver. The AGA, a 501(c6) organization, administers all membership and public policy activities, while the AGA Institute, a 501(c3) organization, runs the organization’s practice, research and educational programs. On a monthly basis, the AGA Institute publishes two highly respected journals, Gastroenterology and Clinical Gastroenterology and Hepatology. The organization's annual meeting is Digestive Disease Week®, which is held each May and is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. For more information, please visit www.gastro.org.

About Gastroenterology

Gastroenterology, the official journal of the AGA Institute, is the most prominent journal in the subspecialty and is in the top one percent of indexed medical journals internationally. The journal publishes clinical and basic science studies of all aspects of the digestive system, including the liver and pancreas, as well as nutrition. The journal is abstracted and indexed in Biological Abstracts, CABS, Chemical Abstracts, Current Contents, Excerpta Medica, Index Medicus, Nutrition Abstracts and Science Citation Index. For more information, visit www.gastrojournal.org.

About Clinical Gastroenterology and Hepatology

The mission of Clinical Gastroenterology and Hepatology is to provide readers with a broad spectrum of themes in clinical gastroenterology and hepatology. This monthly peer-reviewed journal includes original articles as well as scholarly reviews, with the goal that all articles published will be immediately relevant to the practice of gastroenterology and hepatology. For more information, visit www.cghjournal.org.

Aimee Frank | EurekAlert!
Further information:
http://www.gastro.org

More articles from Health and Medicine:

nachricht Mice provide insight into genetics of autism spectrum disorders
28.06.2017 | University of California - Davis

nachricht Correct connections are crucial
26.06.2017 | Charité - Universitätsmedizin Berlin

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can we see monkeys from space? Emerging technologies to map biodiversity

An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.

Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...

Im Focus: Climate satellite: Tracking methane with robust laser technology

Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.

Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...

Im Focus: How protons move through a fuel cell

Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.

As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...

Im Focus: A unique data centre for cosmological simulations

Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.

With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...

Im Focus: Scientists develop molecular thermometer for contactless measurement using infrared light

Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine

Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Plants are networkers

19.06.2017 | Event News

Digital Survival Training for Executives

13.06.2017 | Event News

Global Learning Council Summit 2017

13.06.2017 | Event News

 
Latest News

Mice provide insight into genetics of autism spectrum disorders

28.06.2017 | Health and Medicine

New photoacoustic technique detects gases at parts-per-quadrillion level

28.06.2017 | Physics and Astronomy

Funding of Collaborative Research Center developing nanomaterials for cancer immunotherapy extended

28.06.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>